ADC Therapeutics SA (ADCT) is a publicly traded Healthcare sector company. As of May 20, 2026, ADCT trades at $3.49 with a market cap of $403.20M and a P/E ratio of -3.25. ADCT moved +3.18% today. Year to date, ADCT is -8.99%; over the trailing twelve months it is +50.70%. Its 52-week range spans $1.05 to $4.98. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces ADCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ADC Therapeutics Q1 Revenue $20.03M Beats Estimates, EPS -$0.21 Misses: ADC Therapeutics reported Q1 EPS of -$0.21, missing the -$0.19 estimate, while revenue of $20.03 million edged past forecasts but declined from $23.03 million a year ago. The company holds $231 million cash, a 4.09 current ratio supporting a runway into 2028, and expects LOTIS-5 and LOTIS-7 data by year-end.
| Metric | Value |
|---|---|
| Price | $3.49 |
| Market Cap | $403.20M |
| P/E Ratio | -3.25 |
| EPS | $-0.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.98 |
| 52-Week Low | $1.05 |
| Volume | 592.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $79.17M |
| Net Income | $-136.99M |
| Gross Margin | 0.00% |
3 analysts cover ADCT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.